Archives: 2008 | 2007 | 2006 | 2005
Search Press Releases
You can use 'AND' and 'OR' between keywords.
Keywords must be four or more characters.
General | Financial Results | Receive News by Email
| General |
| Apr 24, 2008 Theravance to Present at the Morgan Stanley Global Healthcare Unplugged Conference |
| Apr 15, 2008 Theravance to Webcast 2008 Annual Meeting of Stockholders on April 22, 2008 |
| Mar 6, 2008 Theravance to Present at the Cowen and Company 28th Annual Health Care Conference |
| Mar 5, 2008 FDA Accepts for Review Theravance's Complete Response to Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections |
| Mar 3, 2008 Theravance Receives Additional Information Regarding FDA Cancellation of Advisory Committee Meeting |
| Feb 26, 2008 GlaxoSmithKline and Theravance Announce Expansion of the Horizon Programme with Start of Large Phase 2b Study of LABA in COPD Patients |
| Feb 23, 2008 FDA Cancels February 27, 2008 Advisory Committee Meeting to Review Telavancin for the Treatment of Complicated Skin and Skin Structure Infections |
| Jan 24, 2008 Theravance to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference |
| Jan 23, 2008 Theravance Announces Closing of $172.5 Million Public Offering of Convertible Subordinated Notes |
| Jan 17, 2008 Theravance Announces Pricing of Convertible Subordinated Notes Offering |
| Jan 15, 2008 Theravance to Present at the 13th Annual Stanford Group Healthcare Conference |
| Jan 15, 2008 Theravance Announces Proposed Offering of $150 Million of Convertible Subordinated Notes Due 2015 |
| Jan 3, 2008 GlaxoSmithKline and Theravance Announce Start of Large Phase 2b ICS and LABA Studies for Asthma in the Horizon Programme |
| Dec 27, 2007 Theravance Receives Notice of Possible Telavancin Review by FDA Advisory Committee |
| Dec 19, 2007 Theravance Announces Appointment of Dr. Mathai Mammen as Head of Research |
| Dec 12, 2007 Theravance Announces Initiation of Phase 1 Clinical Study With Investigational Medicine For Respiratory Disease |
| Dec 5, 2007 Theravance Announces Positive Topline Results In Phase 3 Telavancin Hospital-Acquired Pneumonia Program |
| Oct 31, 2007 Theravance Announces Initiation of Phase 2 Clinical Program with its MABA Compound in COPD |
| Oct 30, 2007 Theravance to Present at Investor Conferences in November 2007 |
| Oct 22, 2007 Theravance Receives FDA Approvable Letter for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections |
| Oct 17, 2007 Theravance Reports Additional Data on Investigational Compound TD-5108 at 2007 American College of Gastroenterology Annual Scientific Meeting |
| Sep 18, 2007 Astellas and Theravance Report Additional Telavancin Data at 47th Annual ICAAC |
| Sep 13, 2007 Theravance Announces Expiration of Stockholder Put Period |
| Sep 6, 2007 Theravance Retains Full Ownership of Gastrointestinal Motility Dysfunction Program and TD-1792 Antibiotic |
| Aug 23, 2007 Theravance to Present at Investor Conferences in September 2007 |
| Jul 31, 2007 Theravance Announces Appointment of Leonard M. Blum as Chief Commercial Officer |
| Jul 9, 2007 Theravance Announces Positive Results from Phase 2 Clinical Study with Investigational Antibiotic in Patients with Complicated Skin and Skin Structure Infections |
| Jul 5, 2007 Dr. Burton Malkiel Appointed to Theravance, Inc. Board of Directors |
| Jun 29, 2007 Theravance Announces that GlaxoSmithKline Will Not Exercise Call Right under Terms of Strategic Alliance to Acquire Additional Shares of Theravance Stock |
| Jun 25, 2007 Theravance Announces Positive Results from Phase 2 Clinical Study in Chronic Constipation with Investigational Compound TD-5108 |
| Jun 20, 2007 Theravance Announces Enrollment of Last Patient in Phase 3 Hospital-Acquired Pneumonia Clinical Program with Investigational Antibiotic, Telavancin |
| May 30, 2007 Theravance Announces Acceptance of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe |
| May 24, 2007 Theravance Announces Results From Preclinical Research and Phase 1 Clinical Studies With Investigational Gastrointestinal Motility Compound Presented at 2007 Digestive Disease Week |
| May 24, 2007 Theravance to Present at Investor Conferences in June 2007 |
| May 1, 2007 Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Complicated Skin and Soft Tissue Infections in Europe |
| Apr 24, 2007 Theravance to Participate in Investor Conferences in May 2007 |
| Apr 18, 2007 Theravance to Webcast 2007 Annual Meeting of Stockholders on April 25, 2007 |
| Apr 9, 2007 Theravance to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference |
| Apr 2, 2007 Theravance Announces Positive Results of Clinical Program in Beyond Advair Collaboration |
| Mar 1, 2007 Theravance to Present at Investor Conferences in March 2007 |
| Feb 20, 2007 Theravance Announces FDA Acceptance of Telavancin NDA |
| Jan 26, 2007 Theravance to Host 2007 Investor R&D Day |
| Jan 26, 2007 Theravance to Present at the 2007 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference |
| Jan 3, 2007 Theravance Initiates Phase 2 Clinical Program with Investigational Heterodimer Antibiotic |
| Jan 3, 2007 Theravance to Present at the 25th Annual JPMorgan Healthcare Conference |
| Dec 7, 2006 Theravance Submits U.S. NDA for Telavancin for the Treatment of Complicated Skin and Skin Structure Infections |
| Nov 20, 2006 Theravance to Present at the Piper Jaffray Health Care Conference |
| Nov 2, 2006 Theravance to Present at Investor Conferences in November 2006 |
| Oct 10, 2006 Theravance Announces Additional Results From Successful Phase 3 Telavancin Complicated Skin and Skin Structure Program |
| Oct 9, 2006 Theravance Initiates Phase 2 Clinical Program In Gastrointestinal Motility Dysfunction |
| Oct 6, 2006 Theravance to Host Investor Conference Call Following Presentation at the Third International Symposium on Resistant Gram-Positive Infections |
| Sep 26, 2006 Telavancin Phase 3 ATLAS Data to Be Presented at Upcoming Conferences |
| Aug 29, 2006 Theravance Announces Upcoming Schedule of Investor Conferences in September 2006 |
| Aug 22, 2006 Theravance Announces Positive Results in Phase 3 Telavancin Complicated Skin and Skin Structure Infection Program |
| Jul 18, 2006 Theravance and Astellas Add Japan to Collaboration on Telavancin, Investigational Antibiotic for Serious Infections |
| Jun 12, 2006 Theravance Announces Second Compound's Entry into Phase 2b Clinical Program in Beyond Advair Collaboration with GlaxoSmithKline |
| May 31, 2006 Theravance to Present at the Pacific Growth Equities Life Sciences Growth Conference |
| May 17, 2006 Theravance to Present at the Bear Stearns Biotech Boston Confab |
| May 16, 2006 Theravance Announces Enrollment of Last Patient in Phase 3 Complicated Skin and Skin Structure Infections Clinical Program with Investigational Antibiotic, Telavancin |
| May 2, 2006 Theravance to Present at the Bank of America Health Care Conference 2006 |
| Apr 21, 2006 Theravance to Present at the Morgan Stanley 2006 Global Healthcare Unplugged Conference |
| Apr 20, 2006 Theravance Announces Initiation of Phase 2b Clinical Program with Investigational Long-Acting Beta Agonist in Beyond Advair Collaboration |
| Apr 19, 2006 Theravance To Webcast 2006 Annual Meeting of Stockholders on April 26, 2006 |
| Mar 30, 2006 Theravance to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference |
| Mar 15, 2006 Theravance to Present at the Bear Biotech West Coast Confab |
| Feb 28, 2006 Theravance to Present at the Cowen & Co. 26th Annual Health Care Conference |
| Feb 28, 2006 Theravance to Present at the Lehman Brothers Ninth Annual Global Healthcare Conference |
| Feb 17, 2006 Theravance to Present at the Citigroup 2006 Healthcare Conference |
| Feb 3, 2006 Theravance to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference |
| Feb 1, 2006 Theravance Announces Pricing of Common Stock Offering |
| Jan 30, 2006 Theravance Announces Proposed Public Offering of Common Stock |
| Jan 10, 2006 Theravance Updates Guidance for Initiation of Phase 2b in the LABA Collaboration |
| Jan 3, 2006 Theravance to Present at the 24th Annual JPMorgan Healthcare Conference |
| Dec 22, 2005 Theravance Announces Results from Phase 1 Clinical Studies With TD-2749, an Investigational Medicine for Gastrointestinal Motility Dysfunction |
| Dec 21, 2005 Theravance Reports Additional Results From Clinical Studies With Investigational Antibiotic Telavancin |
| Dec 21, 2005 Theravance Reports Results From Pre-clinical Studies With Investigational Antibiotic Telavancin |
| Dec 12, 2005 Dr. Eve E. Slater Appointed to Theravance, Inc. Board of Directors |
| Dec 5, 2005 Theravance and Astellas Finalize Collaboration on Telavancin, Investigational Antibiotic for Serious Infections |
| Nov 9, 2005 Theravance to Present at the Credit Suisse First Boston Health Care Conference |
| Nov 7, 2005 Theravance and Astellas to Collaborate on Telavancin, Investigational Antibiotic for Serious Infections |
| Oct 5, 2005 Theravance to Present at BIO InvestorForum |
| Sep 14, 2005 Theravance to Present at Global Pharmaceutical, Biotech & Medtech Conference |
| Aug 30, 2005 Theravance to Present at Thomas Weisel Partners' Healthcare Conference 2005 |
| Jun 28, 2005 Theravance To Webcast Annual Stockholders' Meeting on June 30, 2005 |
| Jun 27, 2005 Theravance Announces Results of Phase 2 Clinical Study Showing 24-Hour Bronchodilation With Investigational Medicine |
| Jun 13, 2005 Theravance Announces Initiation of Phase 1 Clinical Study with Investigational Medicine for Respiratory Disease |
| Jun 6, 2005 Theravance to Present at Thomas Weisel Partners Growth Forum 7.0 |
| Apr 7, 2005 Theravance Announces Results From Clinical And Pre-Clinical Studies With Investigational Antibiotic Telavancin |
| Mar 28, 2005 Theravance Announces Fast Track Designation for Investigational Antibiotic Telavancin |
| Mar 25, 2005 Theravance to Present at Lehman Brothers Eighth Annual Global Healthcare Conference |
| Mar 21, 2005 Theravance Announces GlaxoSmithKline License of Third Respiratory Program |
| Mar 1, 2005 Theravance Announces Publication of Telavancin's Multifunctional Mechanism of Action |
| Feb 17, 2005 Theravance to Present and Participate in Expert Panel on 'New Antibiotics Against New and Old Threats' at BIO CEO and Investor Conference |
| Feb 4, 2005 Theravance To Present At Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference |
| Feb 3, 2005 Theravance Names Michael W. Aguiar Chief Financial Officer |
| Jan 28, 2005 Theravance To Host Investor Presentation |
| Jan 26, 2005 Theravance Announces Initiation of Phase 3 Clinical Studies in Hospital Acquired Pneumonia with Investigational Antibiotic Telavancin |
| Jan 10, 2005 Theravance to Webcast JPMorgan Healthcare |
| Jan 7, 2005 Theravance to Present at the JP Morgan Healthcare Conference |
| Jan 4, 2005 Theravance Announces Initiation of Phase 1 Clinical Study with Investigational Medicine for Gastrointestinal Motility Dysfunction |
| Financial Results |
| Apr 21, 2008 Theravance Reports First Quarter 2008 Financial Results |
| Apr 14, 2008 Theravance to Report First Quarter 2008 Financial Results on April 21, 2008 |
| Feb 14, 2008 Theravance Reports Fourth Quarter and Full Year 2007 Results |
| Jan 31, 2008 Theravance to Report Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008 |
| Oct 25, 2007 Theravance Reports Third Quarter 2007 Financial Results |
| Oct 11, 2007 Theravance to Report Third Quarter 2007 Financial Results on October 25, 2007 |
| Jul 26, 2007 Theravance Reports Second Quarter 2007 Financial Results |
| Jul 12, 2007 Theravance to Report Second Quarter 2007 Financial Results on July 26, 2007 |
| Apr 26, 2007 Theravance Reports First Quarter 2007 Financial Results |
| Apr 12, 2007 Theravance to Report First Quarter 2007 Financial Results on April 26, 2007 |
| Feb 8, 2007 Theravance Reports Fourth Quarter and Full Year 2006 Results |
| Jan 25, 2007 Theravance to Report Fourth Quarter and Full Year 2006 Financial Results on February 8, 2007 |
| Oct 26, 2006 Theravance Reports Third Quarter 2006 Results |
| Oct 12, 2006 Theravance to Report Third Quarter 2006 Financial Results on October 26, 2006 |
| Jul 27, 2006 Theravance Reports Second Quarter 2006 Results |
| Jul 13, 2006 Theravance To Report Second Quarter 2006 Financial Results on July 27, 2006 |
| Apr 27, 2006 Theravance Reports First Quarter 2006 Financial Results |
| Apr 13, 2006 Theravance To Report First Quarter 2006 Financial Results on April 27, 2006 |
| Feb 9, 2006 Theravance Reports Fourth Quarter And Full Year 2005 Financial Results |
| Jan 31, 2006 Theravance to Report Fourth Quarter and Full Year 2005 Financial Results on February 9, 2006 |
| Oct 27, 2005 Theravance Reports Third Quarter 2005 Financial Results |
| Oct 13, 2005 Theravance To Report Third Quarter 2005 Financial Results on October 27, 2005 |
| Jul 27, 2005 Theravance Reports Second Quarter 2005 Financial Results |
| Jul 15, 2005 Theravance To Report Second Quarter 2005 Financial Results on July 27, 2005 |
| May 4, 2005 Theravance Reports First Quarter 2005 Financial Results |
| Apr 18, 2005 Theravance To Report First Quarter 2005 Financial Results on May 4, 2005 |
| Feb 16, 2005 Theravance Reports Fourth Quarter And Full Year 2004 Financial Results |
| Jan 31, 2005 Theravance To Report Fourth Quarter 2004 Financial Results |
Terms of Use Website Admin Contact Theravance Contact Site Map